Abstract
SUMMARYTeicoplanin is a glycopeptide antibiotic which was introduced into clinical use in 1988. Its activity against most Gram‐positive bacteria, including the emergent multiply resistant species, its ease of administration and safety commend its continued use well into the next millennium. The provision of health care in alternative settings such as the home or outpatient clinic has grown in importance, both in Europe and North America. One such service is the provision of parenteral antibiotics for treating a variety of infections in the non‐inpatient setting. This paper aims to review and condense the current published experience of teicoplanin in this setting. Evidence suggests that teicoplanin can be administered effectively using a range of flexible, convenient and safe dosing schedules and is a highly cost‐effective therapeutic option for treating in the non‐inpatient setting many chronic infections, e.g. osteomyelitis and endocarditis, and some acute infections.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
